On May 27, CVS/pharmacy launched a new in-store fundraising campaign named Advancing Medical Research, to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS) and cystic fibrosis (CF). Funds raised through the campaign will benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research, and the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis. Supporters for the 2012 campaign can donate $1 or $3 dollars at the register in CVS/pharmacy locations and online at www.cvs.com/alscff through June 30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56330-cvs-pharmacy-fundraising-campaign-support-als-and-cystic-fibrosis
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Superstar model, producer, television host and designer, Heidi Klum is known for her cutting-edge style and trademark tresses. Now Unilever is tapping the sophisticated fashion icon to help launch new CLEAR SCALP & HAIR BEAUTY THERAPY™, a revolutionary line of nourishing shampoos and conditioners that turns the conventional hair care discussion on its head. This new approach “feeds scalp,” not just the ends, and gives women stronger, more beautiful hair in just seven days.
“When it comes to women’s hair care, the emphasis has traditionally been on the ends, yet 99 percent of hair’s natural strength and beauty comes from the scalp. Scalp is skin and it is important to care for and nourish it just as we care for our skin. NEW CLEAR SCALP & HAIR BEAUTY THERAPY™ feeds the scalp and creates the right foundation for stronger, more beautiful hair in just seven days,” says David Rubin, U.S. Haircare Marketing Director for Unilever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55843-clear-scalp-and-hair-therapy
Approximately 80 million American men and women experience some form of hair loss. Premature balding or thinning hair can often result in a decrease of self esteem. Freedom Laser Therapy of Los Angeles is dedicated to change all that by bringing their iRestore Hair Rejuvenation System to the mass market.
This proven, safe Laser Hair Restoration Technology, otherwise known as phototherapy, is a scientific process providing stimulation to cells in your hair. The 25-year old advanced low-level laser treatment stimulates the scalp, allowing miniaturized and dormant hair follicles to rejuvenate.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54394-freedom-laser-therapy-laser-hair-treatment-regrowth-restoration
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI), is introducing its latest advancement in oxygen therapy. SimplyGo is the only portable oxygen concentrator (POC) to offer continuous flow (up to 2 liters per minute) and pulse-dose delivery in a single device weighing 10 pounds or less. With this combination of capabilities, the SimplyGo POC helps homecare providers manage the therapy and lifestyle needs of nearly all oxygen users.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54713-philips-respironics-simplygo-portable-oxygen-concentrator
http://www.glosunspa.com ~ Houston Tanning Salon ~ Phone (713) 662-9200 Glo Sun Spa is the most luxurious spot in Houston for indoor tanning and skin care. Glo is actually a working showroom that features all the newest technology from the top manufacturers worldwide. Equipment choices include VersaSpa, Lumiere Light Therapy, Ergoline, KBL America, Tan America, Sportareddo, Dr. Mueller, Hydration Station, and Sun Italia. When you become a member at Glo Sun Spa, you can indulge in all the finest equipment available worldwide! Enjoy! Glo Sun Spa, 3273 Southwest Freeway, Houston, TX 77027, (713) 662-9200 http://www.glosunspa.com
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the FDA clearance of the pocket-sized PICO◊ system, a single use Negative Pressure Wound Therapy (NPWT) system. PICO is cleared for use both in a hospital and homecare setting and expands the use of NPWT from the traditional wound care population to include a wider range of patients undergoing orthopaedic surgery, plastic surgery and general surgical procedures. This FDA clearance follows the recent successful launch of PICO in Europe, Canada, and Australia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51011-smith-nephew-pico-system-fda-approval-npwt
